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Background. Immune complexes may cause an irreversible
onset of chronic renal disease. Most patients with chronic renal
disease undergo a final common pathway, marked by glomeru-
losclerosis and interstitial fibrosis. We attempted to draw a
molecular map of anti-glomerular basement membrane (GBM)
glomerulonephritis in mice using oligonucleotide microarray
technology.
Methods. Kidneys were harvested at days 1, 3, 7, 11, and
16 after inducing glomerulonephritis by using anti-GBM an-
tibody. In parallel with examining the biochemical and histo-
logic changes, gene expression profiles were acquired against
five pooled control kidneys. Gene expression levels were cross-
validated by either reverse transcription-polymerase chain re-
action (RT-PCR), real-time PCR, or immunohistochemistry.
Results. Pathologic changes in anti-GBM glomerulonephritis
were confirmed in both BALB/c and C57BL/6 strains. Among
the 13,680 spotted 65mer oligonucleotides, 1112 genes showing
significant temporal patterns by permutation analysis of vari-
ance (ANOVA) with multiple testing correction [false discovery
ratio (FDR) < 0.05] were chosen for cluster analysis. From the
expression profile, acute inflammatory reactions characterized
by the elevation of various cytokines, including interleukin (IL)-
1 and IL-6, were identified within 3 days of disease onset. After
7 days, tissue remodeling response was prominent with highly
induced extracellular-matrix (ECM) genes. Although cytokines
related to lymphocyte activation were not detected, monocyte
or mesangial cell proliferation-related genes were increased.
Tumor necrosis factor-a (TNF-a) and nuclear factor-jB
(NF-jB) pathway were consistently activated along the entire
disease progression, inducing various target genes like comple-
ment 3, IL-1b, IL-6, Traf1, and Saa1.
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Conclusion. We made a large-scale gene expression time ta-
ble for mouse anti-GBM glomerulonephritis model, providing
a comprehensive overview on the mechanism governing the ini-
tiation and the progression of inflammatory renal disease.
Large-scale gene expression analysis provides a logical
approach in studying the detailed mechanisms behind the
pathogenesis of various diseases. Using DNA microarray
containing tens of thousands of genes, the genes regulat-
ing the key steps in disease initiation and progression can
be identified [1]. The identification of specific genes in-
volved in the pathogenesis of human diseases may reveal
molecular targets for diagnosis and drug development [2].
As the clinical implications were evident in cancer pa-
tients [3], microarray can be applied to kidney diseases in
classifying subsets of disease states with different clinical
outcomes and in providing more efficient tools in clinical
nephrology [4, 5].
Most glomerular disorders show a pattern of progres-
sive decline in renal function with glomerulosclerosis and
tubulointerstitial fibrosis [6]. The fibrotic change might
serve as a final common pathway on the initial insults to
glomeruli. A serial cascade of events triggered by cer-
tain stimuli (i.e., inflammation, nephrotoxic drugs, and
ureteral obstruction) converge to a fibrogenic response
in the glomerular and tubulointerstitial compartments
of kidney. If we can address the pathogenesis of the
fibrogenic process in terms of target molecules, it will
cover the glomerulotubulointerstitial interplay. To this
date, extensive researches have focused on listing the to-
tal transcripts involved in the development of various
nephropathies in order to find genes that may be po-
tentially involved in the pathogenesis [7–10]. Yano et
al [9] compared the expression profile of 18,326 genes
in primary human proliferating mesangial cells with IgA
nephropathy to that in the control subjects and listed 203
human transcripts related to IgA nephropathy.
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In the present study, we measured genome-wide gene
expression levels in renal tissues of anti-glomerular base-
ment membrane (GBM) glomerulonephritis model using
oligonucleotide microarray technology. The roles of re-
cruit and resident cells in the production of cytokines,
growth factors, and extracellular matrix (ECM) compo-
nents were systematically investigated. The major role of
nuclear factor-jB (NF-jB) was suggested to be in the reg-
ulation of inflammatory as well as fibrogenic responses of
the anti-GBM glomerulonephritis model system.
METHODS
Anti-GBM glomerulonephritis model
Basically we followed the previously described method
to make anti-GBM glomerulonephritis model [11].
Briefly, GBM protein was extracted from rat kidneys and
immunized to New Zealand White rabbits to raise anti-
GBM antibody. The rabbit sera were heat-inactivated and
immunoglobulin (Ig) fractions were isolated by protein A
columns (Pierce, Rockford, IL, USA). Nephritis was in-
duced by intravenous injection of 0.3 mg/g weight of rab-
bit anti-GBM IgG in 6-week-old female mice of BALB/c
and C57BL/6 strains (N = 20 in each strain). Four mice
at a time were sacrificed from each strain serially on days
1, 3, 7, 11, and 16. Using metabolic cages, we collected
24-hour urines and measured body weights before sacri-
fice. One half of a kidney was processed for histologic and
immunohistochemical studies and the remaining one and
one half were used for enzyme-linked immunosorbent
assay (ELISA) and DNA microarray. All animal experi-
ments were conducted in accordance with the NIH Guide
for the Care and Use of Laboratory Animals.
Light microscopy
Formalin-fixed tissues were embedded in paraffin and
4 lm sections were stained with periodic acid-Schiff
(PAS). The amount of glomerular collagen was graded
in 30 glomeruli according to the guide (delete the space)
lines provided by Kagami et al [12]: 0, no mesangial stain-
ing; 1, focally increased mesangial staining at less than
25%; 2, 25% to 50% of glomerular tuft stained; 3, 50% to
75% of glomerular tuft stained; and 4, more than 75% of
glomerular tuft stained. Interstitial collagen was scored
according to the guidelines provided by Yamamoto et al
[13]: 0, normal; 1, less than 10% of the area involved; 2,
10% to 30% involved; 3, 30% to 50% involved; and 4,
more than 50% involved.
ELISA
Chopped cortical tissue was suspended in 1 mL of
serum-free RPMI (Sigma Chemical Co., St. Louis, MO,
USA) and incubated in 5% CO2 at 37◦C. After 48
hours, the conditioned media were collected, mixed
with proteinase inhibitors [phenylmethylsulfonyl fluo-
ride (PMSF), aprotinin, leupeptin, and pepstatin A], and
stored at −70◦C until analysis. Fibronectin concentration
was quantified by competitive inhibitory ELISA as de-
scribed previously [14]. Total protein concentration was
measured by BCA protein assay kit (Pierce). Transform-
ing growth factor-b1 (TGF-b1) level in the urine was mea-
sured by ELISA (Quantikine human TGF-b1) (R&D
Systems, Minneapolis, MN, USA) after activation of the
latent TGF-b1 with 1 N HCl and neutralization with 1.2
N NaOH/0.5 mol HEPES. Serum and urinary creatinine
were measured by alkaline picrate method as mg/mL
(Sigma Chemical Co.). Fibronectin/total protein ratios in
conditioned media and urinary TGF-b1/creatinine ratios
were calculated as lg/mg and pg/mg, respectively.
Oligonucleotide microarray
Pooled total RNA from five control mice were used
as the reference group in all experiments. Three out
of the four RNAs extracted from anti-GBM glomeru-
lonephritis mice each at days 1, 3, 7, 11, and 16 were
used for triplicate experiments at each five time points.
Total RNA was prepared by using TriZol reagent (Life
Technologies, Gaithersburg, MD, USA). The array used
in this experiment was the Caltech 16K Custom-Oligo
array. The oligonucleotide probes were purchased from
Operon Technologies (Alameda, CA, USA) (70-mer)
and Compugen-Sigma-Genosys (Jamesburg, NJ, USA)
(65-mer) and inkjet printed by Agilent Technologies
(Palo Alto, CA, USA). First and second strand cDNA
synthesis was initiated by incubating 5 lg of total RNA
with 5 lL of T7 promoter primer in nuclease-free water
at 65◦C for 10 minutes. Fluorescent Linear Amplification
Kit (Agilent Technologies) was used [15]. Briefly, the re-
sulting mixture was incubated with 4 lL of 5× first strand
buffer, 2 lL of 0.1 mol/L dithiothreitol (DTT), 1 lL of 10
mmol/L deoxynucleoside triphosphate (dNTP), 1 lL of
200 ng/lL random hexamers, 1 lL of 200 U/lL Moloney-
murine leukemia virus-reverse transcription (MMLV-
RT), 0.5 lL of 40 U/lL RnaseOUT, and 1 lL of Triton
X-100 at 40◦C for 4 hours. After cDNA synthesis, the
sample was in vitro transcribed and labeled by incubat-
ing it with 4 lL of cyanine-3 (Cy3)-CTP (6.0 mmol/L)
(Perkin Elmer Life Sciences, Norwalk, CT, USA) or 4 lL
of cyanine-5 (Cy5)-CTP (4.0 mmol/L) (Perkin Elmer
Life Sciences), 20 lL of transcription buffer, 8 lL of
NTP mixture, 6 lL of 0.1 mol/L DTT, 0.5 lL of Rnase-
OUT, 0.6 lL of inorganic pyrophosphatase, 0.8 lL of
T7 RNA polymerase, and 20.1 lL of nuclease-free wa-
ter at 40◦C for 3 hours. Before hybridization, 8 lg of
Cy3-CTP–labeled cRNA and 8 lg of Cy5-CTP–labeled
cRNA were mixed together with 2.5 lL of Mouse Cot-
1 DNA (Invitrogen, Carlsbad, CA, USA), 2.5 lL of
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deposition control target (Operon Technologies), and
12.5 lL of 2× hybridization buffer (Agilent Technolo-
gies). The mixture was centrifuged at 12,000 rpm for 3
minutes after it was boiled for 2 minutes. About 24 lL
of the mixture was hybridized on the array at 65◦C for
16 hours. After hybridization, the array was washed with
solution I [0.5× standard sodium citrate (SSC), 0.01%
sodium dodecyl sulfate (SDS), and 1 mmol/L DTT in
nuclease-free water], solution II (0.25× SSC, 0.01% SDS,
and 1 mmol/L DTT in nuclease-free water), and solu-
tion III (0.06× SSC and 1 mmol/L DTT in nuclease-free
water), respectively. The arrays were scanned using the
Agilent G2505A scanner (Agilent Technologies) and the
array data were extracted using Agilent G2566AA Ex-
traction Software version A.6.1.1 (Agilent Technologies).
Data analysis
Fluorescence intensity was processed and measured
using Agilent G2566AA Extraction Software version
A.6.1.1. Intensity data were imported to an in-house
microarray database. Variance stabilizing normalization
by Huber et al [16] was applied with the “vsn” pack-
age in Bioconductor using the R statistical package.
After performing intensity-dependent global LOWESS
regression, spatial and intensity dependent effects were
managed by pin group LOWESS normalization follow-
ing by the approach of Yang et al [17]. F test for each
probe was performed to discover the genes showing
significant temporal patterns. It was suggested by our
quantile-quantile plot analysis, however, that the nor-
mality assumption for the data set was not held [18]
(see http://www.snubi.org/publication/antiGBM/). Resid-
ual quantiles were deviated from the theoretic quantiles.
Since the distributions of the observed statistics are un-
known, an empiric reference set was generated by per-
muting the sample labels. For each probe, we randomly
permuted 100,800 times, following the rationale of Dwass
[19], out of the theoretic 168,168,138 exact ways of as-
signing 15 objects to five groups with triplicates (i.e.,
15!/(3!)15). Then P value for each probe was calculated
as the rank of the observed statistic, Fi, among the em-
piric distributions divided by the permutation size. To
manage the multiple hypothesis testing problem, the P
value cutoff was decided by determining the false dis-
covery rate (FDR) following the scheme of Storey and
Tibshirani [20]. FDR is the proportion of false positives
among all genes called significant. Hence, the estimated
number of false positives in the present study is pre-
sumed to be about 55 out of the 1112 genes called sig-
nificant at FDR < 0.05. Cluster analysis was performed
for the 1112 (FDR < 0.05) genes having significant
temporal patterns by MITree-K partitional clustering
algorithm [21] (http://www.snubi.org/software/MITree/).
The cluster analysis result with full annotations is
provided at our supplement web page (Data A
at http://www.snubi.org/publication/antiGBM/). Clusters
were mapped onto biologic pathways and sorted on the
order of matching significance using ArrayXPath [22].
The gene expression data set was submitted to the Gene
Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/)
under the accession numbers, GSM15078-GSM-15029,
GSE954-GSE958, and GSE969.
Reverse transcription-polymerase chain reaction
(RT-PCR) and real-time PCR
The first strand cDNA was synthesized from 1 lg of
total RNA using reverse transcriptase and 1 lmol/L of
oligo-dT primer. Each cDNA sample was amplified by
using specific primers against complement component 3
(C3) (sense 5′-GTGACATCCCAGTCACA-3′ and anti-
sense 5′-CTCAAACTCTGCGGAGA-3′), serum amy-
loid A1 (Saa1) (sense 5′-GTTCACGAGGCTTTCCA-3′
and antisense 5′-GTCAGGCAGTCCAGGA-3′), inter-
leukin 1 beta (IL-1b) (sense 5′-AGAAGCTGTGGCAG
CTA-3′ and antisense 5′-TGAGGTGCTGATGTACCA-
3′), fibronectin 1 (Fn1) (sense 5′-GTGATCCCCATGAA
GCAA-3′ and antisense 5′-AGGGTGACCAACTGT
CA-3′), collagen, type III, alpha 1 (Col3a1) (sense 5′-
AAAGAGGAGGTCCTGGAA-3′ and antisense 5′-CT
TGCCAGGAGCACCA-3′), complement component 1,
q subcomponent, alpha polypeptide (C1qa) (sense 5′-GT
CGCTTCATCTGTGCA-3′ and antisense 5′-CGGGG
ATCGTTTATTCCA-3′), complement component 1, q
subcomponent, beta polypeptide (C1qb) (sense 5′-GA
CTACGGGGCTACACA-3′ and antisense 5′-GCAGT
CAAGGGGGTGA-3′), complement component 1, q
subcomponent, c polypeptide (C1qc) (sense 5′-AGGGC
CGATACAAACAGA-3′ and antisense 5′-CCGATGG
ATCAGGAACCA-3′), TGF-b1 (TGFb1) (sense 5′-
CTGCGCTTGCAGAGA-3′ and antisense 5′-CAGGGT
CCCAGACAGA-3′), connective tissue growth factor
(Ctgf) (sense 5′-CCAAGCAGCTGGGAGA-3′ and
antisense 5′-TGCTTCTCCAGTCTGCA-3′), and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
(sense 5′-ACCACAGTCCATGCCATCAC-3′ and
antisense 5′-TCCACCACCCTGTTGCTGTA-3′).
Specific bands were analyzed after agarose gel elec-
trophoresis.
Real-time PCR was performed in a LightCycler us-
ing DNA Master SYBR Green I dye (Roche Molecular
Biochemicals, Pleasanton, CA, USA). Measurements of
the threshold cycles were made at the end of each exten-
sion step by the second-derivative method using Light-
Cycler software version 4.0 (Roche Molecular Biochem-
icals). Melting curve analysis was performed to confirm
the identity of peaks of interest in all samples. PCR-
amplified fragments of the respective genes were cloned
into pGEM easy T vector (Promega, Madison, WI, USA),
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which was used as standard DNAs for quantification, and
results were normalized with the amount of GAPDH
mRNA.
Immunofluorescence staining
For immunofluorescent staining of mouse kidney, tis-
sue sections were fixed in formalin/phosphate-buffered
saline (PBS) and embedded with paraffin. Visualization
was performed using Cy3 antirabbit IgG (Jackson Im-
munoResearch, West Grove, PA, USA) followed by flu-
orescence microscopy (Zeiss Axioplan using a Hama-
matsu ORCA CCD camera). Briefly, tissues were fixed
with 2% paraformaldehyde in PBS. After permeabiliza-
tion using 0.5% NP-40, cells were blocked in 0.2% gelatin
and 0.5% bovine serum albumin (BSA) in PBS. Primary
anti-Traf1, anti-Traf2, and Traf-3 antibodies from Santa
Cruz Biotechnologies (Santa Cruz, CA, USA) (1:200 di-
lution) were incubated with kidney tissues and Traf pro-
teins were visualized using Cy5 antirabbit IgG (Jackson
ImmunoResearch) and fluorescence microscopy (Zeiss).
RESULTS
Expression profile of anti-GBM glomerulonephritis
Following the previously described protocols [11], we
made an anti-GBM glomerulonephritis model by inject-
ing rabbit antirat GBM antibody into two strains of
mouse, BALB/c and C57BL/c. Although these two were
different in human leukocyte antigen (HLA) types (H-2b
for C57BL/6 and H-2d for BALB/c), they responded to
immune complex in the same manner and to similar ex-
tents. Edema, proteinunria and decreased serum protein
levels appeared within the first day of disease induction in
both strains (Fig. 1A). Moreover, signs of late changes like
fibrogenic responses at around 7 to 11 days were apparent
in both strains. We measured the mesangial matrix score
as well as interstitial fibrosis score in PAS-stained kidney
tissues (Fig. 1B and C). According to the serial changes in
clinicopathologic findings, we divided the disease into two
periods: a heterologous phase of acute glomerulonephri-
tis at 1 to 3 days and a homologous phase with following
glomerulosclerosis and tubulointerstitial fibrosis at 7 to
16 days. Along with the biochemical and histologic pa-
rameters, our anti-GBM model covers the entire disease
span from acute glomerulonephritis to tubulointerstitial
fibrosis. To draw a composite map of gene expression pro-
files using oligonucleotide microarray containing 13,618
mouse genes, we performed triplicate microarray exper-
iments for anti-GBM glomerulonephritis model at days
1, 3, 7, 11, and 16 with 15 microarray slides.
We selected 1112 genes (6.89%) that showed signifi-
cant temporal patterns across the time intervals by per-
mutation analysis of variance (ANOVA) with multiple
comparison and estimated FDR (<0.05). The expres-
sion profiles were divided into 50 clusters accord-
ing to their temporal expression patterns (Data A at
http://www.snubi.org/publication/antiGBM/). In the het-
erologous phase, the groups of genes related to acute
phase reactants and cytokines were elevated as early as
days 1 to 3, while a small portion of selected genes showed
a gradual decrease in expression during this period. For
example, several genes like potassium channels or aqua-
porins were decreased. After day 7 of the disease, the
groups of genes related to immune response and fibrosis
were increased during homologous phase. Transcripts of
growth factors, channel protein and metabolic enzymes
were decreased at around days 11 to 16. In addition,
several unknown expressed sequence tags (ESTs) were
markedly decreased in late phase. All these findings ex-
plain the major changes in pathologic examination as well
as biochemical analysis.
After the gene expression profiles were clustered
into 50 clusters, we mapped all microarray probe
identifiers onto biologic pathways using ArrayXPath
[22] (http://www.snubi.org/software/ArrayXPath/). The
nonredundant 1260 BioCarta nodes in 277 murine path-
ways were 100% covered by our 18,326 probes. Ar-
rayXPath successfully mapped 139 probe identifiers out
of the 1112 members in the 50 clusters (12.5%) onto
209 BioCarta pathways (Data B at http://www.snubi.
org/software/ArrayXPath/ArrayXPath antiGBM.html).
In cluster 15, 89 genes were up-regulated slightly in
days 1 and 3 and higher in days 7, 11, and 16. Among
them, 13 genes could be successfully plotted onto Bio-
Carta pathways. Especially five pathways like D4-GDI
signaling pathway, T-cytotoxic cell surface molecule, T-
helper cell surface molecule, effects of calciurenin in
keratinocyte differentiation, and Fc epsilon receptor I
signaling in mast cells showed statistically significant
match to eight unique genes. Especially three genes
(Pla2g4a, Prkcb, and Fcer1g) were related to the Fc ep-
silon receptor I signaling in mast cell while another four
genes (Mapk1, Hras1, Vav1, and Lyn) for this pathway
were also chosen in other clusters. Expression of Pla2g4a
encoding cytosolic phospholipase A2 plays an important
role in eicosanoid metabolism and bleomycin-induced
pulmonary fibrosis [23]. Cluster 45 showed highly ele-
vated expression levels from days 3 to 7 and then mod-
erately elevated levels after days 11 and 16. Five out of
the 17 members were mapped onto pathways. Rac1 and
Vav1 were commonly mapped onto many inflammatory
pathways including Rac1 cell motility, T cell receptor, B
cell receptor, and Ras-independent pathway in natural
killer cell-mediated cytotoxicity. The genes in cluster 5
showed different expression pattern, which were moder-
ately up-regulated in days 1 and 3, but afterwards down-
regulated continuously. This cluster included proteolytic
enzymes like kallikreins (i.e., Klk9, Klk13, Klk16, Klk21,
and Klk27), Enpp1, Dpp7, Proc, Acp5, Cspg5, Dipep1,
and receptors or transporters like Sigirr, Accn5, Fabp7,
and Abcb1a.
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Fig. 1. Biochemical and pathologic analysis on anti-glomerular basement membrane (GBM) glomerulonephritis model. (A) Changes of body
weights at each time point were monitored throughout the disease progression. The level of serum creatinine, serum proteins and urinary proteins
were measured to calculate serum or urine protein/creatinine ratios. Each value is an average of four mice with error bar displaying the standard
deviation. (B) Pathologic analysis showed marked changes in glomeruli (upper row) and interstitia (lower row) throughout the disease progression
[periodic acid-Schiff (PAS) 400× for the glomeruli, 100× for the interstitial]. (C) The degree of pathologic changes could be transformed to
parametric indices for mesangial matrix and interstitial fibrosis. Each value is averaged among four mice with error bar displaying the standard
deviation.
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Table 1. Expression profiles of cytokines
Fold change (mean ± SD)
Category Symbol Day 1 Day 3 Day 7 Day 11 Day 16
Fibrosis 0.931 ± 0.327 1.251 ± 0.056 1.942 ± 0.000 2.064 ± 0.071 1.994 ± 0.237
Ctgf 1.969 ± 0.840 1.415 ± 0.512 1.337 ± 0.619 0.649 ± 0.961 0.804 ± 0.505
Tgfb1i4 0.025 ± 0.170 1.397 ± 0.303 1.332 ± 0.529 0.492 ± 0.338 0.802 ± 0.469
Tgfb1i1 0.516 ± 0.317 0.750 ± 0.180 0.791 ± 0.157 1.202 ± 0.176 0.755 ± 0.368
Tgfb1 −0.221 ± 0.426 ND 0.456 ± 0.322 ND ND
Growth/apoptosis Tnfa −0.218 ± 0.428 0.317 ± 0.022 0.299 ± 0.193 0.267 ± 0.231 −0.022 ± 0.141
Pdgfa 0.121 ± 0.338 1.278 ± 0.120 0.907 ± 0.143 1.182 ± 0.104 0.306 ± 0.623
Egf −0.434 ± 0.104 −1.630 ± 0.251 −2.318 ± 0.136 −1.617 ± 0.221 −1.702 ± 0.166
Monocyte Scya2 0.499 ± 0.056 2.783 ± 0.052 2.699 ± 0.278 3.009 ± 0.151 3.025 ± 0.296
IL-1b 0.537 ± 0.055 0.652 ± 0.016 0.851 ± 0.785 1.472 ± 0.264 1.626 ± 0.020
IL-6 0.563 ± 0.036 1.300 ± 0.919 1.117 ± 0.789 2.722 ± 0.094 2.140 ± 1.513
Scya6 ND 0.352 ± 0.250 1.529 ± 0.964 1.063 ± 0.164 2.031 ± 0.452
Gcr1 ND 1.319 ± 0.932 1.786 ± 0.110 1.366 ± 0.558 1.878 ± 0.545
Scya5 0.385 ± 0.353 1.144 ± 0.004 1.274 ± 0.066 1.091 ± 0.268 0.479 ± 0.153
Ccr5 1.036 ± 0.599 1.422 ± 1.006 1.880 ± 0.310 1.916 ± 0.173 1.821 ± 0.229
T cell/B cell Tnfsf5 0.179 ± 0.208 0.245 ± 0.276 0.779 ± 0.016 0.652 ± 0.242 −0.113 ± 0.110
IL-2 0.405 ± 0.182 0.082 ± 0.062 −0.055 ± 0.348 −0.369 ± 0.087 −0.092 ± 0.177
IL-10 0.212 ± 0.170 −0.261 ± 0.185 −0.482 ± 0.340 −0.514 ± 0.304 0.671 ± 0.001
IL-4 ND 0.219 ± 0.154 0.369 ± 0.261 0.359 ± 0.208 ND
IL-17 −0.538 ± 0.175 −0.639 ± 0.063 −0.957 ± 0.312 −1.212 ± 0.101 0.576 ± 0.613
IL-18 −0.068 ± 0.040 −0.036 ± 0.088 −0.215 ± 0.048 0.061 ± 0.198 0.365 ± 0.133
IL-15 −0.827 ± 0.071 −1.078 ± 0.156 −1.549 ± 0.118 −1.336 ± 0.248 −1.626 ± 0.108
IL-5 −0.413 ± 0.081 −0.104 ± 0.185 0.291 ± 0.319 0.023 ± 0.134 0.016 ± 0.062
Inflammatory cytokines related to monocyte activation
In this immune complex disease model, we focused
on the changes of total cytokines presented in our ar-
ray. We found patterns of immune responses through the
gene expression profiles. As shown in Table 1, we catego-
rized cytokines in four groups: those related to fibrosis,
growth/apoptosis, monocyte, and lymphocyte. Members
of the growth/apoptosis cytokines such as epidermal
growth factor (EGF) [24], insulin-like growth factor-1
(IGF-1) [25], and interleukins like IL-15 [26] were down-
regulated. These cytokines were previously proven to be
involved in renal diseases and may be good therapeutic
targets for minimizing fibrogenic effects in renal disease
patients.
We looked for evidences of mesangial cell activation
by recording the elevation of monocyte cytokines such
as tumor necrosis factor-alpha (TNF-a), chemokine re-
ceptors (Ccr1 and Ccr5), small inducible cytokine family
[monocyte chemoattractant protein-1 (MCP-1), regu-
lated upon activation, normal T cell expressed and se-
creted (RANTES), and multidrug resistance-associated
peptide (MRP1)] and interleukins (IL-1b and IL-6).
However, interleukins involved in the stimulation of T
or B lymphocytes were not increased in this model, while
some of interleukins like IL-15 were decreased.
Glomerulosclerosis and interstitial fibrosis
The expression of cytokines plays a critical role during
the pathogenesis of inflammatory kidney disease, which
is involved in tissue remodeling and repair by increasing
ECM components. One of the most extensively investi-
gated cytokines in the context of renal disease is TGF-b
[27, 28]. In our microarray experiment, the transcript of
TGF-b1 was not detected more than two fold of baseline
(Table 1). However, we confirmed increased urinary ex-
cretion of TGF-b1 as measured by ELISA (Fig. 2A) and
up-regulation in renal tissue by RT-PCR (Fig. 2B). The
evidence for the presence of TGF-b1 in inflammatory re-
nal disease was supported by the elevation of target genes
like Tgfbi, Tgfb1i1, and Tgfb1i4 (Table 1). Connective tis-
sue growth factor (CTGF) has been suggested to induce
interstitial fibrosis directed by TGF-b1 [29]. In this study,
CTGF was expressed as early as the first day of disease
induction preceding TGF-b1 expression, which means
that it might also be involved in inflammatory responses
(Table 1) (Fig. 2B).
After 11 days of the disease, ECM proteins were accu-
mulated in the glomeruli and interstitia (Fig. 1B). Fn1 and
collagen type III isotype alpha1 (Col3a1) were elevated
in the affected kidney beginning from day 7 as observed
through microarray analysis (Fig. 2C). We confirmed
the expression changes of Fn1 and Col3a1 by RT-PCR
(Fig. 2B) and immunofluorescence staining (Fig. 2D).
NF-jB–mediated gene expression
One of the major culprits of anti-GBM glomeru-
lonephritis is NF-jB, which can modulate inflamma-
tory responses in various diseases. Target genes for NF-
jB were marked elevated at any time points in this
model, either. While some of them were elevated at a
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Fig. 2. Molecular changes related to glomeruloscerosis or interstitial fibrosis. (A) The protein levels of urinary transforming growth factor-b (TGF-
b1) and renal parenchymal fibronectin were measured by enzyme-linked immunosorbent assay (ELISA). Each value is an average of four mice
with error bar displaying the standard deviation. (B) The transcript levels of Tgfb1, Ctgf , Fn1, and Col3a1 at indicated time points were analyzed by
reverse transcription-polymerase chain reaction (RT-PCR) using total RNA from BALB/c and C57BL/6. (C) Using immunofluorescence analysis,
the level of Col3a1 in C57BL/c mouse renal cortex was monitored (100×). (D) Log2 transformed ratio of Fn1 and Col3a1 in DNA microarray was
plotted with standard deviation (N = 3).
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Table 2. Gene expression profiles of nuclear factor-jB (NF-jB) and its target genes
Fold change (mean ± SD)
Category Symbol Day 1 Day 3 Day 7 Day 11 Day 16
Acute, sustained Saa1 3.249 ± 0.635 3.314 ± 0.304 3.096 ± 0.427 2.494 ± 0.564 1.949 ± 0.955
Egr1 1.760 ± 0.315 2.252 ± 0.537 2.743 ± 0.255 2.688 ± 0.091 2.262 ± 0.326
Birc5 1.544 ± 0.017 2.015 ± 0.123 1.780 ± 0.138 1.695 ± 0.069 1.571 ± 0.107
Early, transient Nfjb 0.460 ± 0.261 1.245 ± 0.039 1.153 ± 0.113 0.672 ± 0.053 0.491 ± 0.105
Ptgs2 0.381 ± 0.221 1.588 ± 1.122 0.277 ± 0.196 0.922 ± 0.623 0.604 ± 0.235
Rel 0.519 ± 0.188 1.422 ± 0.273 1.274 ± 0.025 1.509 ± 0.201 0.822 ± 0.179
Traf1 0.521 ± 0.219 1.125 ± 0.146 0.971 ± 0.071 0.847 ± 0.203 0.097 ± 0.128
Irf1 0.250 ± 0.137 1.242 ± 0.006 1.170 ± 0.095 1.026 ± 0.227 0.913 ± 0.183
Early, sustained Atf3 0.938 ± 0.177 1.806 ± 0.035 1.800 ± 0.115 1.741 ± 0.081 1.717 ± 0.036
Birc2 0.268 ± 0.242 1.336 ± 0.179 1.917 ± 0.027 1.812 ± 0.127 1.586 ± 0.273
C3 0.870 ± 0.563 1.512 ± 0.157 2.307 ± 0.323 2.160 ± 0.967 1.881 ± 0.014
Crol 0.296 ± 0.568 2.408 ± 0.244 2.196 ± 0.323 1.913 ± 0.095 1.762 ± 0.812
Junb 1.021 ± 0.146 2.473 ± 0.306 3.008 ± 0.156 2.779 ± 0.227 2.301 ± 0.244
Myc 0.027 ± 0.225 2.174 ± 0.583 2.706 ± 0.089 2.249 ± 0.348 2.249 ± 0.320
Trl2 0.017 ± 0.273 1.903 ± 0.053 2.417 ± 0.157 2.259 ± 0.154 2.118 ± 0.446
Bcl3 0.150 ± 0.193 2.096 ± 0.319 2.119 ± 0.869 2.261 ± 0.140 2.300 ± 0.302
Vcam1 0.250 ± 0.061 2.303 ± 0.211 2.717 ± 0.081 3.118 ± 0.335 2.124 ± 0.410
Scay2 −0.701 ± 0.101 1.681 ± 0.058 2.258 ± 0.156 2.515 ± 0.381 1.955 ± 0.227
Late Mekk1 0.268 ± 0.029 0.915 ± 0.359 1.329 ± 0.045 1.459 ± 0.264 1.148 ± 0.512
Bcl2a1c 0.094 ± 0.234 0.534 ± 0.642 1.268 ± 0.033 1.893 ± 0.201 2.057 ± 0.557
Bcl2a1d −0.118 ± 0.055 0.102 ± 0.752 0.949 ± 0.004 1.907 ± 0.232 1.932 ± 0.379
IL-1b 1.184 ± 0.366 0.965 ± 0.798 1.806 ± 0.263 1.691 ± 0.009 1.909 ± 0.029
IL-6 0.563 ± 0.325 1.300 ± 0.919 1.117 ± 0.789 2.722 ± 0.094 2.140 ± 1.513
specific time point, NF-jB seemed to work all through the
disease course (Table 2). Within 24 hours, acute phase
reactants like serum amyloid proteins (Saa1) and early
growth response 1 (Egr1) were increased. These genes
might be transcribed upon immune complex deposition
in the glomeruli through the activation of endogenous
nuclear factors and other NF-jB target genes. Signals
inducing those target genes can also up-regulate new
sets of NF-jB and rel oncogene (Rel) transiently at day
3, which might be involved in the maintenance of tar-
get genes. Spikes of NF-jB and Rel transcription may
possibly induce other transcription factors like ATF-3,
Jun-B, and Myc, which eventually lead to late phase re-
sponses such as interstitial fibrosis and tissue remodel-
ing. Interestingly, NF-jB at late phase directed the tran-
scription of antiapoptotic genes like BCL3, MEKK1,
Bcl1a1c, and Bcl2a1d, which suggest that the induction
of NF-jB may prevent tissue destruction. We confirmed
the expression of IL-1b , IL6, Saa1, and C3 genes by
RT-PCR in both strains (Fig. 3A). In addition, we per-
formed real-time RT-PCR analysis for IL-1b in par-
allel to crosscheck the microarray data by different
platform.
As a target for NF-jB, we found that series of comple-
ments were up-regulated in our model. Renal parenchy-
mal cells expressed the complements because we
perfused mouse kidney to remove any circulating cells
(Table 2) (Fig. 4). Specifically, C1qa, C1qb, C1qc, and C3
were expressed at day 11. We confirmed those findings by
performing RT-PCR for both strains of mice (Fig. 4A).
We also counted the copy number of C1qc transcript us-
ing real-time RT-PCR method, which also showed con-
sistent pattern in the sequential changes of C1qc gene in
both strains (Fig. 4B)
We also focused on Traf family genes that transduce
the signaling from TNF to NF-jB and are bona fide tar-
gets of NF-jB by positive feedback. In spite of the weak
increase in transcript messages of Traf1 in both RT-PCR
and microarray (Fig. 5A and B), the signal of the Traf1
protein was quite high in the glomeruli of disease kid-
ney (Fig. 5C). Traf2 and Traf3 were also increased in our
model at later phases, but present in a weaker signal as
observed from immunofluorescence staining.
DISCUSSION
While the anti-GBM model is a well-known system for
the renal disease progression, we made an effort to under-
stand the disease in view of the complete transcriptomic
map using 13,680 mouse genes. We monitored the tem-
poral changes in gene expression together with clinico-
pathologic variables in the same mouse. Previous studies
on RNA expression in experimental kidney disease have
shown that renal mRNA levels for ECM components and
cytokines can be used as a prognostic marker [5, 30]. Our
results lead to the composition of more intensive maps
with multiple parameters. From this data, we found the
central role of monocytes, but not lymphocytes, in the
progression of our renal disease model. NF-jB might play
an important role in directing responses to the immune
complex of the glomerulus.
One of the key components responsible for direct-
ing the final common pathway of fibrotic responses in
inflammatory nephropathy might be TGF-b1 and its
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Fig. 3. Reverse transcription-polymerase
chain reaction (RT-PCR) and real-time
PCR analysis on nuclear factor-jB (NF-jB)
target genes. (A) The transcript levels of
NF-jB target genes (IL-6, IL-1b , Saa1, and
C3), selected from Table 2, were analyzed
by RT-PCR in both BALB/c and C57BL/6
mice. (B) Using real-time PCR method, the
copy number of IL-1b was measured in both
BALB/c and C57BL/6 mice.
downstream target molecules like CTGF [31]. Although
our microarray result did not detect an increase of TGF-
b1, the transcript was detected at late phase of the disease,
as observed using ELISA and RT-PCR. The presence and
action of TGF-b1 was indirectly uncovered in our mi-
croarray data through discovering the up-regulation of
target genes at late phase. These results support the pre-
vious notion that TGF-b1 leads to fibrogenic effects in
inflammatory nephropathy. On the other hand, the ex-
pression of CTGF was expressed quite ahead of TGF-b1
within 24 hours after immune complex formation in our
study. The expression of CTGF modulates tissue response
at early stage of glomerulonephritis [31]. Even the early
expression of CTGF in glomerular diseases can be used
as a biomarker [32].
The disease progression of our model mice occurred
so rapidly that they die within 3 weeks after the antibody
injection. Because it might not be enough to recruit lym-
phocytes, we could detect local immune reactions medi-
ated by mesangial cells (Table 1). Nonetheless, mesangial
cell activation has been suggested to be a central response
of inflammatory models of renal diseases and various hu-
man nephropathies [33, 34]. Immune complex deposition
acutely triggered the circulating neutrophil activation to
produce the cytokines for mesangial cells. Traf can medi-
ate the inflammatory response to nuclei through NF-jB
activation [35]. We could monitor the elevation of Traf1
message in mesangial cells within 24 hours in immunoflu-
orescence staining. Although the role of Traf1 in NF-jB
activation is still controversial [36, 37], it may be impor-
tant to mediate mesangial response for NF-jB activation
in this model.
We noticed many growth factors like EGF or IGF
and ESTs without functional annotation were suppressed
with progression of the disease, which might be a puta-
tive target for minimizing the progression to fibrogenic
change (Supplement Data A). Another therapeutic ap-
proach may be antagonizing proinflammatory molecules
like platelet-derived growth factor (PDGF) by using neu-
tralizing antibodies, which have been proven to be effec-
tive in reducing proliferation in animal models [34]. If we
have information regarding upstream targets governing
proinflammatory molecules, we may be able to block in-
tracellular signals simultaneously. Currently, we focused
our attention to several transcription factors. The regu-
latory repertoire of transcription factor families appears
to be pivotal for the modulation of gene expression. Nu-
merous proinflammatory genes have regulation motifs
for NF-jB [38, 39]. We listed the elevation of NF-jB tar-
get genes in our microarray data (Table 2). Since there
is a close relationship between NF-jB and mediators of
cell activation, it is possible that disruption of NF-jB acti-
vating pathways may effectively influence mesangial cell
activation.
A large number of studies have made use of quan-
titative RT-PCR, serial analysis of gene expression
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Fig. 4. Increased expression of complement
genes in anti-glomerular basement membrane
(GBM) glomerulonephritis model. (A) Log2
transformed ratio of complement proteins in
DNA microarray was plotted with standard
deviation (N = 3) at each time point. (B) The
levels of transcripts of C1qa, C1qb , C1qc, and
C3 were analyzed by reverse transcription-
polymerase chain reaction (RT-PCR) using
total RNA from BALB/c and C57BL/6. (C)
The copy number of C1qc transcript was mea-
sured by real-time PCR.
(SAGE), or single nucleotide polymorphism (SNP) to
find biomarkers for prognosis or disease progression [4,
40, 41]. Microarray gene expression profiling might be
used to determine disease markers and to understand
pathogenesis [42]. Although not unique, our observa-
tions highlight the importance of subdividing the stages of
glomerulonephritis. The detailed staging by gene expres-
sion profiles may enable scientists and clinicians to tailor
therapeutic strategies by fine-tuning their regimen to the
individual patient’s disease stage. Additionally, current
study as well as a variety of recent studies mentioned here
validate data from previous studies on anti-GBM disease
and provide important directions for further investiga-
tions. Application of the information obtained from this
study is not confined to anti-GBM disease but expandable
to most basic and clinical researches on progressive renal
diseases.
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